Targeted DNA RNA Sequencing Market
Report ID: SQMIG35J2330
Report ID: SQMIG35J2330
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35J2330 |
Region:
Global |
Published Date: May, 2026
Pages:
157
|Tables:
118
|Figures:
77
Global Targeted Dna Rna Sequencing Market size was valued at USD 7.52 Billion in 2024 and is poised to grow from USD 8.33 Billion in 2025 to USD 18.85 Billion by 2033, growing at a CAGR of 10.82% during the forecast period (2026-2033).
Targeted DNA/RNA sequencing market centers on diagnostic services that interrogate selected genomic regions to deliver actionable genetic information with higher sensitivity and lower cost than whole-genome approaches. Its primary driver is the escalating demand for precision medicine where clinicians require rapid, interpretable mutation profiles to guide therapy selection for oncology and inherited disorders. Historically the field moved from Sanger sequencing to next-generation platforms that enabled multiplexed amplicon and hybrid-capture panels, and commercial solutions such as Oncomine and Foundation Medicine assays accelerated clinical translation. As sequencing costs declined and regulatory clarity improved, adoption expanded across clinical settings and global reference laboratories.
A key trend driving the global targeted DNA RNA sequencing sector is payer acceptance of biomarker-driven care, because when reimbursement and guidelines recognize targeted assays, hospitals and labs integrate panels into diagnostic pathways which increases testing volumes and incentivizes investments in automation and bioinformatics. Consequently manufacturers and labs can lower per-sample costs and expand menu offerings into liquid biopsy and minimal residual disease monitoring, creating real-world value such as guiding EGFR-directed therapy in lung cancer or tracking MRD in acute leukemia. Similarly pharmaceutical reliance on genomic selection for trials generates sustained demand, which in turn stimulates partnerships, regulatory submissions, and geographic expansion into emerging markets, globally too.
How is AI improving accuracy and throughput in the targeted DNA/RNA sequencing market?
Targeted DNA and RNA sequencing allows the detection of clinically significant variants and expression signals in specific regions of the genome. AI has many applications in this area; it has enhanced the accuracy of basecalling through improved error models and has enabled more intelligent variant calling that helps to distinguish true low frequency signal from background noise. AI also allows for improved detection of RNA isoforms and interpretations from splice sites, thus increasing the diagnostic yield for these tests. Furthermore, AI enables improved throughput through automation of sample quality control, adaptive design of assays, and accelerated cloud-based analysis that reduces the need for manual review. Real world deployments of AI enabled pipelines and lab automation are already shortening turnaround and raising confidence in targeted assays.
In April 2026, Illumina released DRAGEN v4.5 which embeds AI enabled variant interpretation to resolve difficult to map regions and speed analysis, supporting market growth by improving accuracy in targeted assays and increasing lab throughput through automated processing and scalable analytics.
Market snapshot - (2026-2033)
Global Market Size
USD 7.52 Billion
Largest Segment
Amplicon Sequencing
Fastest Growth
Hybridization Capture
Growth Rate
10.82% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global targeted dna rna sequencing market is segmented by method, product, application, end-user and region. Based on method, the market is segmented into Hybridization Capture, Amplicon Sequencing and Molecular Inversion Probes (MIPs). Based on product, the market is segmented into Instruments, Reagents & Kits and Bioinformatics Software. Based on application, the market is segmented into Oncology Biomarker Testing, Hereditary Disease Screening, Infectious Disease and Pharmacogenomics. Based on end-user, the market is segmented into Research Institutes, Diagnostic Labs and Pharma & Biotech. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
What Role do Hybridization Capture Play in Improving Assay Sensitivity in Targeted DNA RNA Sequencing?
Based on the global targeted DNA RNA sequencing market growth, hybridization capture segment dominates because its probe-based enrichment enables comprehensive, uniform coverage across targets and supports DNA and RNA targets from clinical specimens. Its flexibility to scale panels and integrate with high throughput workflows drives preference among clinical and research customers seeking biomarker detection. The targeted DNA RNA sequencing market owes its leadership position to its strong assay performance/reliability, ability to work with degraded samples, and large investment by suppliers in high performance probes.
However, Amplicon Sequencing is emerging as the most rapidly expanding approach due to fast turnaround, low input requirements and straightforward workflow suited to diagnostic laboratories. Innovation in multiplex PCR chemistry, automation compatibility and rising demand for focused panels drive adoption and unlock new application opportunities in targeted DNA RNA sequencing.
How are Bioinformatics Software Addressing Variant Interpretation Challenges in Targeted DNA RNA Sequencing?
Bioinformatics software segment dominates because advanced algorithms and validated pipelines are essential for accurate variant calling, fusion detection and integrative DNA RNA analysis in clinical and research workflows. The ability to manage centralized data, analytical layers or viewing the data from the sequencing process and reporting tools allow laboratory management to convert sequenced information into useable information while also meeting quality and compliance standards. An investment in interoperability between the instruments used to generate data and the warehoused knowledgebases is required to establish the view that software will serve as a primary source for the targeted DNA RNA sequencing market.
However, reagents & kits are emerging as the most rapidly expanding area driven by demand for standardized ready workflows that simplify laboratory adoption and ensure reproducibility. Innovations in extraction chemistries, library preparation and targeted enrichment kits, with regulatory cleared offerings and automation compatibility, accelerate deployment across clinical and research applications.
To get detailed segments analysis, Request a Free Sample Report
Why does North America Dominate the Global Targeted DNA RNA Sequencing Market?
As per the global targeted DNA RNA sequencing market share, As North America dominates due to an ecosystem that aligns scientific capability, commercial innovation, and clinical adoption. A dense concentration of academic medical centers and research institutes drives discovery and early validation of targeted panels. Commercialization and scale of laboratory operations have been accelerated by large biotech and diagnostic companies along with specialized services. Clear regulatory pathways and a mature reimbursement environment promote clinical integration; deep venture and institutional investment help to iterate technology. Deep bioinformatics talent, combined with established sample logistics networks, allow for rapid deployment across research and healthcare. Biopharma companies, hospitals, and contract research organizations work together, making North America the major player to continue leading and influencing most of the world in standard development & product innovation.
United States Targeted DNA RNA Sequencing Market
Targeted DNA RNA sequencing market in United States is shaped by extensive translational research and strong industry infrastructure. Targeted assays for both oncology and rare disease are adopted by integrated healthcare systems and leading academic institutions while commercial laboratories and both sequencing and testing companies provide broad access to testing services. Close collaboration on assay development and clinical trial use between biopharma and diagnostic companies, combined with advanced informatics capabilities that facilitate the interpretation and reporting of results, meets clinical requirements.
Canada Targeted DNA RNA Sequencing Market
Targeted DNA RNA Sequencing Market in Canada benefits from coordinated research networks and centralized laboratory systems that support clinical implementation. Publicly oriented health systems and collaborative genomics initiatives create pathways for integrating targeted assays into care and research. Partnerships between domestic biotech firms and international companies enhance technology transfer and capacity building, while academic medical centers contribute to validation, variant interpretation, and workforce development that underpin market progress.
What is Driving the Rapid Expansion of Targeted DNA RNA Sequencing Market in Europe?
Based on global targeted DNA RNA sequencing regional forecast, Europe is experiencing rapid expansion driven by a confluence of research excellence, supportive policy frameworks, and growing clinical demand for precision diagnostics. Collaboration between academic organizations/conglomerates and corporate partners throughout the country creates opportunities for conducting cross-border studies as well as standardizing assays between different countries. National programs in upscale markets help to expand laboratory testing capacity and bring in private sector support for the laboratory industry. A strong network of specialty lab and contract research organizations offers ways to scale testing services, while regional manufacturers and reagent suppliers provide support for supply chain integrity. Increasing integration of targeted sequencing into oncology pathways and translational research, together with evolving regulatory clarity and payer engagement, positions Europe as a dynamic growth region with differentiated strengths across major countries.
Germany Targeted DNA RNA Sequencing Market
Targeted DNA RNA sequencing market in Germany is anchored by strong industrial and clinical capabilities. Laboratory development of assays and their subsequent distribution relies heavily on both large-scale diagnostics manufacturers, specialized laboratories, and supporting entities within academic medical tertiary hospitals/healthcare facilities or other research organizations performing clinical validation. These collaborative networks between both industry and healthcare organizations provide opportunities for the translation of applications for oncology addressed and rare disease diagnostics.
United Kingdom Targeted DNA RNA Sequencing Market
Targeted DNA RNA sequencing market in United Kingdom is characterized by rapid innovation and strong translational pipelines. Leading research institutions and a proactive clinical research environment accelerate validation of targeted panels, and dynamic biotech clusters foster commercialization. Collaboration between hospitals, research institutions, and industries will enable clinical trials and everyday usage by successfully implementing a Collaborative framework that involves all of them working together as much as possible.
France Targeted DNA RNA Sequencing Market
Targeted DNA RNA sequencing market in France is emerging through coordinated national genomics efforts and expanding clinical adoption. Collaboration between academic research centers and hospitals are developing targeted methods of analyzing research results; greater participation from biotech start-ups will help them commercialise their products. Sequencing is emphasised within thde clinical pathfolders of training and investment in building laboratories for this purpose will create a supportive climate for further industry growth and use in clinical practice.
How is Asia Pacific Strengthening its Position in Targeted DNA RNA Sequencing Market?
As per global targeted DNA RNA sequencing regional outlook, Asia Pacific is strengthening its position by building capacity across manufacturing, clinical laboratories, and bioinformatics, supported by targeted public and private investment in genomics and life sciences. Local companies are developing new assays and reagent manufacturing, which will lessen the need for outside suppliers and create solutions that can be developed close to the point-of-care. Clinical needs for precision cancer medicine, monitoring infectious diseases, and diagnosing rare diseases is also expanding the installation of hospital networks. Partnerships across the globe with technology providers & more specialization for analyzer use will speed the transition of assay development into practice. Regulatory modernization and development of research infrastructure further enhance the region ability to integrate targeted sequencing into healthcare and research ecosystems, positioning key markets as important contributors to global innovation.
Japan Targeted DNA RNA Sequencing Market
Targeted DNA RNA sequencing market in Japan is supported by strong diagnostics companies, advanced clinical laboratories, and close collaboration between industry and academic medical centers. The hospital networks and medical research facilities influence the ability to develop a clinical evidence base to support the use of medical products across all of the medical specialties by providing access to clinical studies. Also through the development of improved bioinformatics capabilities at the hospitals and collaborating with worldwide industrial partners.
South Korea Targeted DNA RNA Sequencing Market
Targeted DNA RNA sequencing market in South Korea is propelled by an agile biotechnology sector, strong information technology integration, and concentrated clinical research activity. Collaborating with international partners and specialty laboratories is facilitating the development and introduction of assays into the market at a rapid pace. Concentrating on analytics, efficiency in laboratories, and developing export strategies supports the ability of the region to be more competitive as well as have the ability to satisfy both domestic and international customers.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Drivers
Increasing Adoption Of Precision Medicine
Advances In Sequencing Technology
Restraints
High Cost Of Specialized Assays
Limited Skilled Workforce Availability
Request Free Customization of this report to help us to meet your business objectives.
Competition in global targeted DNA RNA sequencing market outlook is intensifying as platform owners and reagent specialists pursue M&A, distribution deals, and workflow innovations to lock in capture chemistries and clinical pipelines. Notable examples include Illumina’s contested acquisition of GRAIL, veterinary test distribution partnerships such as PetDx with Antech Diagnostics, and technology tie ups like Sequentify’s automation collaborations that speed sample prep and panel deployment.
Top Player’s Company Profile
Recent Developments
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the global targeted DNA RNA sequencing industry is poised for strong growth driven primarily by increasing adoption of precision medicine, which encourages use of focused panels to guide therapy and clinical trials. A second driver is advances in sequencing technology and AI enabled analysis that boost accuracy and throughput. A notable restraint remains the high cost of specialized assays which can limit adoption among smaller labs. The high concentration of academic medical centres, commercial laboratories and favourable reimbursement in North America has led to its dominance of the region. Hybridisation capture is leading in the method segment with its probe based enrichment method providing complete and uniform coverage and being compatible with clinical samples.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 7.52 Billion |
| Market size value in 2033 | USD 18.85 Billion |
| Growth Rate | 10.82% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Targeted DNA RNA Sequencing Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Targeted DNA RNA Sequencing Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Targeted DNA RNA Sequencing Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Targeted DNA RNA Sequencing Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Targeted Dna Rna Sequencing Market size was valued at USD 7.52 Billion in 2024 and is poised to grow from USD 8.33 Billion in 2025 to USD 18.85 Billion by 2033, growing at a CAGR of 10.82% during the forecast period (2026-2033).
Competition in targeted DNA RNA sequencing is intensifying as platform owners and reagent specialists pursue M&A, distribution deals, and workflow innovations to lock in capture chemistries and clinical pipelines. Notable examples include Illumina’s contested acquisition of GRAIL, veterinary test distribution partnerships such as PetDx with Antech Diagnostics, and technology tie ups like Sequentify’s automation collaborations that speed sample prep and panel deployment. 'Illumina Inc.', 'Thermo Fisher Scientific', 'Qiagen NV', 'Agilent Technologies', 'Roche Diagnostics', 'Pacific Biosciences', 'Oxford Nanopore Technologies', 'BGI Genomics', 'Twist Bioscience', 'Integrated DNA Technologies', 'Foundation Medicine (Roche)', 'Guardant Health', 'Tempus Labs', 'Grail Inc.', 'NeoGenomics Laboratories', 'Burning Rock Biotech', 'Personal Genome Diagnostics', 'Caris Life Sciences', 'Genoptix (Novartis)', 'Natera Inc.'
Increasing adoption of precision medicine has expanded demand for targeted DNA and RNA sequencing because clinicians require focused molecular profiles to guide personalized therapies, monitor minimal residual disease, and stratify patients for tailored treatment paths. Payers and healthcare systems prioritize diagnostic approaches that improve treatment selection and reduce unnecessary interventions, encouraging incorporation of targeted sequencing into clinical workflows. Manufacturers respond by developing panels aligned with therapeutic targets, strengthening collaborations with pharmaceutical developers and diagnostic labs, thereby reinforcing market uptake and broader clinical integration over time.
Liquid Biopsy Integration: Targeted DNA and RNA sequencing is increasingly applied to minimally invasive liquid biopsy workflows for disease detection and treatment monitoring, expanding beyond oncology into transplant surveillance and infectious disease applications. This trend drives demand for high sensitivity assays and standardized protocols, fosters collaborations between diagnostics developers and clinical laboratories, and encourages regulatory bodies and payers to consider supportive frameworks. Improved sample processing and reporting harmonization are becoming priorities to enable reliable longitudinal data for clinical decision making and evidence generation.
Why does North America Dominate the Global Targeted DNA RNA Sequencing Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
